US Tariffs on Pharma: Zydus, Dr Reddy’s at highest risk, says Jefferies; Check impact on other Indian pharma stocks

US Tariffs on Pharma: Given Zydus Lifesciences and Dr Reddy’s Laboratories have high US sales exposure with ~45% and 43% sales contribution, Jefferies believes they are at highest risk among generics.